Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation

Vanessa C. Fernandes, Volha A. Golubeva, Giuliano Di Pietro, Cara Shields, Kwabena Amankwah, Thales C. Nepomuceno, Giuliana de Gregoriis, Renata B.V. Abreu, Carly Harro, Thiago T. Gomes, Ricceli F. Silva, Guilherme Suarez-Kurtz, Fergus J Couch, Edwin S. Iversen, Alvaro N.A. Monteiro, Marcelo A. Carvalho

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Genetic testing for BRCA1, a DNA repair protein, can identify carriers of pathogenic variants associated with a substantially increased risk for breast and ovarian cancers. However, an association with increased risk is unclear for a large fraction of BRCA1 variants present in the human population. Most of these variants of uncertain clinical significance lead to amino acid changes in the BRCA1 protein. Functional assays are valuable tools to assess the potential pathogenicity of these variants. Here, we systematically probed the effects of substitutions in the C terminus of BRCA1: the N- and C-terminal borders of its tandem BRCT domain, the BRCT-[N-C] linker region, and the 1 and 1 helices in BRCT-[N] and -[C]. Using a validated transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396 –1863), we assessed the functional impact of 99 missense variants of BRCA1. We include the data obtained for these 99 missense variants in a joint analysis to generate the likelihood of pathogenicity for 347 missense variants in BRCA1 using VarCall, a Bayesian integrative statistical model. The results from this analysis increase our understanding of BRCA1 regions less tolerant to changes, identify functional borders of structural domains, and predict the likelihood of pathogenicity for 98% of all BRCA1 missense variants in this region recorded in the population. This knowledge will be critical for improving risk assessment and clinical treatment of carriers of BRCA1 variants.

Original languageEnglish (US)
Pages (from-to)5980-5992
Number of pages13
JournalJournal of Biological Chemistry
Volume294
Issue number15
DOIs
StatePublished - Jan 1 2019

Fingerprint

Amino Acid Substitution
Virulence
Tumors
Assays
Substitution reactions
BRCA1 Protein
Amino Acids
DNA
Risk assessment
Neoplasms
Repair
Fusion reactions
Association reactions
Genetic Testing
Statistical Models
DNA Repair
Ovarian Neoplasms
Population
Testing
Breast Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Fernandes, V. C., Golubeva, V. A., Pietro, G. D., Shields, C., Amankwah, K., Nepomuceno, T. C., ... Carvalho, M. A. (2019). Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. Journal of Biological Chemistry, 294(15), 5980-5992. https://doi.org/10.1074/jbc.RA118.005274

Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1 : Implications for clinical annotation. / Fernandes, Vanessa C.; Golubeva, Volha A.; Pietro, Giuliano Di; Shields, Cara; Amankwah, Kwabena; Nepomuceno, Thales C.; de Gregoriis, Giuliana; Abreu, Renata B.V.; Harro, Carly; Gomes, Thiago T.; Silva, Ricceli F.; Suarez-Kurtz, Guilherme; Couch, Fergus J; Iversen, Edwin S.; Monteiro, Alvaro N.A.; Carvalho, Marcelo A.

In: Journal of Biological Chemistry, Vol. 294, No. 15, 01.01.2019, p. 5980-5992.

Research output: Contribution to journalArticle

Fernandes, VC, Golubeva, VA, Pietro, GD, Shields, C, Amankwah, K, Nepomuceno, TC, de Gregoriis, G, Abreu, RBV, Harro, C, Gomes, TT, Silva, RF, Suarez-Kurtz, G, Couch, FJ, Iversen, ES, Monteiro, ANA & Carvalho, MA 2019, 'Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation', Journal of Biological Chemistry, vol. 294, no. 15, pp. 5980-5992. https://doi.org/10.1074/jbc.RA118.005274
Fernandes, Vanessa C. ; Golubeva, Volha A. ; Pietro, Giuliano Di ; Shields, Cara ; Amankwah, Kwabena ; Nepomuceno, Thales C. ; de Gregoriis, Giuliana ; Abreu, Renata B.V. ; Harro, Carly ; Gomes, Thiago T. ; Silva, Ricceli F. ; Suarez-Kurtz, Guilherme ; Couch, Fergus J ; Iversen, Edwin S. ; Monteiro, Alvaro N.A. ; Carvalho, Marcelo A. / Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1 : Implications for clinical annotation. In: Journal of Biological Chemistry. 2019 ; Vol. 294, No. 15. pp. 5980-5992.
@article{eaa3fd749c064d90a015ba68d975d818,
title = "Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation",
abstract = "Genetic testing for BRCA1, a DNA repair protein, can identify carriers of pathogenic variants associated with a substantially increased risk for breast and ovarian cancers. However, an association with increased risk is unclear for a large fraction of BRCA1 variants present in the human population. Most of these variants of uncertain clinical significance lead to amino acid changes in the BRCA1 protein. Functional assays are valuable tools to assess the potential pathogenicity of these variants. Here, we systematically probed the effects of substitutions in the C terminus of BRCA1: the N- and C-terminal borders of its tandem BRCT domain, the BRCT-[N-C] linker region, and the 1 and 1 helices in BRCT-[N] and -[C]. Using a validated transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396 –1863), we assessed the functional impact of 99 missense variants of BRCA1. We include the data obtained for these 99 missense variants in a joint analysis to generate the likelihood of pathogenicity for 347 missense variants in BRCA1 using VarCall, a Bayesian integrative statistical model. The results from this analysis increase our understanding of BRCA1 regions less tolerant to changes, identify functional borders of structural domains, and predict the likelihood of pathogenicity for 98{\%} of all BRCA1 missense variants in this region recorded in the population. This knowledge will be critical for improving risk assessment and clinical treatment of carriers of BRCA1 variants.",
author = "Fernandes, {Vanessa C.} and Golubeva, {Volha A.} and Pietro, {Giuliano Di} and Cara Shields and Kwabena Amankwah and Nepomuceno, {Thales C.} and {de Gregoriis}, Giuliana and Abreu, {Renata B.V.} and Carly Harro and Gomes, {Thiago T.} and Silva, {Ricceli F.} and Guilherme Suarez-Kurtz and Couch, {Fergus J} and Iversen, {Edwin S.} and Monteiro, {Alvaro N.A.} and Carvalho, {Marcelo A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1074/jbc.RA118.005274",
language = "English (US)",
volume = "294",
pages = "5980--5992",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "15",

}

TY - JOUR

T1 - Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1

T2 - Implications for clinical annotation

AU - Fernandes, Vanessa C.

AU - Golubeva, Volha A.

AU - Pietro, Giuliano Di

AU - Shields, Cara

AU - Amankwah, Kwabena

AU - Nepomuceno, Thales C.

AU - de Gregoriis, Giuliana

AU - Abreu, Renata B.V.

AU - Harro, Carly

AU - Gomes, Thiago T.

AU - Silva, Ricceli F.

AU - Suarez-Kurtz, Guilherme

AU - Couch, Fergus J

AU - Iversen, Edwin S.

AU - Monteiro, Alvaro N.A.

AU - Carvalho, Marcelo A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Genetic testing for BRCA1, a DNA repair protein, can identify carriers of pathogenic variants associated with a substantially increased risk for breast and ovarian cancers. However, an association with increased risk is unclear for a large fraction of BRCA1 variants present in the human population. Most of these variants of uncertain clinical significance lead to amino acid changes in the BRCA1 protein. Functional assays are valuable tools to assess the potential pathogenicity of these variants. Here, we systematically probed the effects of substitutions in the C terminus of BRCA1: the N- and C-terminal borders of its tandem BRCT domain, the BRCT-[N-C] linker region, and the 1 and 1 helices in BRCT-[N] and -[C]. Using a validated transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396 –1863), we assessed the functional impact of 99 missense variants of BRCA1. We include the data obtained for these 99 missense variants in a joint analysis to generate the likelihood of pathogenicity for 347 missense variants in BRCA1 using VarCall, a Bayesian integrative statistical model. The results from this analysis increase our understanding of BRCA1 regions less tolerant to changes, identify functional borders of structural domains, and predict the likelihood of pathogenicity for 98% of all BRCA1 missense variants in this region recorded in the population. This knowledge will be critical for improving risk assessment and clinical treatment of carriers of BRCA1 variants.

AB - Genetic testing for BRCA1, a DNA repair protein, can identify carriers of pathogenic variants associated with a substantially increased risk for breast and ovarian cancers. However, an association with increased risk is unclear for a large fraction of BRCA1 variants present in the human population. Most of these variants of uncertain clinical significance lead to amino acid changes in the BRCA1 protein. Functional assays are valuable tools to assess the potential pathogenicity of these variants. Here, we systematically probed the effects of substitutions in the C terminus of BRCA1: the N- and C-terminal borders of its tandem BRCT domain, the BRCT-[N-C] linker region, and the 1 and 1 helices in BRCT-[N] and -[C]. Using a validated transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396 –1863), we assessed the functional impact of 99 missense variants of BRCA1. We include the data obtained for these 99 missense variants in a joint analysis to generate the likelihood of pathogenicity for 347 missense variants in BRCA1 using VarCall, a Bayesian integrative statistical model. The results from this analysis increase our understanding of BRCA1 regions less tolerant to changes, identify functional borders of structural domains, and predict the likelihood of pathogenicity for 98% of all BRCA1 missense variants in this region recorded in the population. This knowledge will be critical for improving risk assessment and clinical treatment of carriers of BRCA1 variants.

UR - http://www.scopus.com/inward/record.url?scp=85064344065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064344065&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA118.005274

DO - 10.1074/jbc.RA118.005274

M3 - Article

C2 - 30765603

AN - SCOPUS:85064344065

VL - 294

SP - 5980

EP - 5992

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 15

ER -